These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 19276159)

  • 1. Estrogen-related receptor-alpha antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts.
    Chisamore MJ; Wilkinson HA; Flores O; Chen JD
    Mol Cancer Ther; 2009 Mar; 8(3):672-81. PubMed ID: 19276159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a novel small molecule subtype specific estrogen-related receptor alpha antagonist in MCF-7 breast cancer cells.
    Chisamore MJ; Cunningham ME; Flores O; Wilkinson HA; Chen JD
    PLoS One; 2009 May; 4(5):e5624. PubMed ID: 19462000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
    Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
    Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
    Thewes V; Simon R; Schroeter P; Schlotter M; Anzeneder T; Büttner R; Benes V; Sauter G; Burwinkel B; Nicholson RI; Sinn HP; Schneeweiss A; Deuschle U; Zapatka M; Heck S; Lichter P
    Cancer Res; 2015 Feb; 75(4):720-31. PubMed ID: 25643697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors.
    Lu D; Kiriyama Y; Lee KY; Giguère V
    Cancer Res; 2001 Sep; 61(18):6755-61. PubMed ID: 11559547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
    Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
    J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-497 downregulation contributes to cell proliferation, migration, and invasion of estrogen receptor alpha negative breast cancer by targeting estrogen-related receptor alpha.
    Han L; Liu B; Jiang L; Liu J; Han S
    Tumour Biol; 2016 Oct; 37(10):13205-13214. PubMed ID: 27456360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling.
    Tian J; Wang Y; Zhang X; Ren Q; Li R; Huang Y; Lu H; Chen J
    J Exp Clin Cancer Res; 2017 Nov; 36(1):153. PubMed ID: 29096683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen induces estrogen-related receptor alpha gene expression and chromatin structural changes in estrogen receptor (ER)-positive and ER-negative breast cancer cells.
    Hu P; Kinyamu HK; Wang L; Martin J; Archer TK; Teng C
    J Biol Chem; 2008 Mar; 283(11):6752-63. PubMed ID: 18174157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.
    Zhan Y; Zhang Y; Liu C; Zhang J; Smith WW; Wang N; Chen Y; Zheng L; He L
    Cancer Prev Res (Phila); 2012 Jun; 5(6):864-73. PubMed ID: 22496388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
    Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity.
    Deblois G; Hall JA; Perry MC; Laganière J; Ghahremani M; Park M; Hallett M; Giguère V
    Cancer Res; 2009 Aug; 69(15):6149-57. PubMed ID: 19622763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer.
    Stein RA; Chang CY; Kazmin DA; Way J; Schroeder T; Wergin M; Dewhirst MW; McDonnell DP
    Cancer Res; 2008 Nov; 68(21):8805-12. PubMed ID: 18974123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells.
    Stein RA; Gaillard S; McDonnell DP
    J Steroid Biochem Mol Biol; 2009 Mar; 114(1-2):106-12. PubMed ID: 19429439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GGNBP2 acts as a tumor suppressor by inhibiting estrogen receptor α activity in breast cancer cells.
    Lan ZJ; Hu Y; Zhang S; Li X; Zhou H; Ding J; Klinge CM; Radde BN; Cooney AJ; Zhang J; Lei Z
    Breast Cancer Res Treat; 2016 Jul; 158(2):263-76. PubMed ID: 27357812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice.
    Chambliss KL; Wu Q; Oltmann S; Konaniah ES; Umetani M; Korach KS; Thomas GD; Mineo C; Yuhanna IS; Kim SH; Madak-Erdogan Z; Maggi A; Dineen SP; Roland CL; Hui DY; Brekken RA; Katzenellenbogen JA; Katzenellenbogen BS; Shaul PW
    J Clin Invest; 2010 Jul; 120(7):2319-30. PubMed ID: 20577047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
    Weir HM; Bradbury RH; Lawson M; Rabow AA; Buttar D; Callis RJ; Curwen JO; de Almeida C; Ballard P; Hulse M; Donald CS; Feron LJ; Karoutchi G; MacFaul P; Moss T; Norman RA; Pearson SE; Tonge M; Davies G; Walker GE; Wilson Z; Rowlinson R; Powell S; Sadler C; Richmond G; Ladd B; Pazolli E; Mazzola AM; D'Cruz C; De Savi C
    Cancer Res; 2016 Jun; 76(11):3307-18. PubMed ID: 27020862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
    Garner F; Shomali M; Paquin D; Lyttle CR; Hattersley G
    Anticancer Drugs; 2015 Oct; 26(9):948-56. PubMed ID: 26164151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel compound LingH2-10 inhibits the growth of triple negative breast cancer cells in vitro and in vivo as a selective inverse agonist of estrogen-related receptor α.
    Ning Y; Chen H; Du Y; Ling H; Zhang L; Chen L; Qi H; Shi X; Li Q
    Biomed Pharmacother; 2017 Sep; 93():913-922. PubMed ID: 28715872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.